

## **Clinical Standards**

5-11 Theobalds Road, London WC1X 8SH Tel: 020 7092 6160 | Fax: 020 7092 6001 clinical.standards@rcpch.ac.uk

## NICE Omalizumab for the treatment of severe persistent allergic asthma in children aged 6 and over and adults Assessment Report

Name		
Position		Consultant Neonatal Paediatrician
Specialty group, special interest group or CSAC		Royal College of Paediatrics and Child Health Clinical Standards Committee and Medicines Committee
Page number	Section number	Comments
30	2.6.1	The description on Omalizumab use in children <12 years is not clear.  The message is confusing and does not give a clear guidance to clinicians.